Effects of kikyo-to on sore throat pain associated with acute upper respiratory tract infection: a multicenter, randomized, controlled trial

Effects of kikyo-to on sore throat pain associated with acute upper respiratory tract infection: a multicenter, randomized, controlled trial - Multicenter study of kikyo-to for upper respiratory tract infection (mKURI)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035591

Enrollment

Registered

2019-01-21

Start date

2019-02-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

upper respiratory tract infection

Interventions

Patients receive 2.5 g herbal extract preparation of kikyo-to, a Japanese herbal medicine, dissolved in 100 mL of hot water. Patients receive a 2.5 g placebo (lactose), dissolved in 100 mL of hot wate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with upper respiratory tract infections and a complaint of sore throat, aged >= 20 and < 65 years were registered.

Exclusion criteria

Exclusion criteria: Allergy to kikyo-to or lactose, aldosteronism, myopathy, known hypokalemia, pregnancy or possibility of pregnancy, breastfeeding, current usage of kikyo-to, inurgent condition, unable to participate in the study because of dementia, visual impairment, unable to answer or complete the study form

Design outcomes

Primary

Measure	Time frame
Primary outcome is the difference on sore throat VAS scale between 30 minutes after kikyo-to is taken.	—

Secondary

Measure	Time frame
Primary outcome is the difference of sore throat VAS scale between 10 minutes after kikyo-to is taken.	—

Countries

Japan

Contacts

Public ContactTomoko Hirata

Akashi Medical Center Department of Medical Quality and Safety

yakuzaika.2@amc1.jp0789361101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026